NS-229 is currently being evaluated in a phase 2 trial in patients with eosinophilic granulomatosis with polyangiitis. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ...

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage ...

1) Bell, CF., Lau, M., Shen, Q. Clinical and Economic Characteristics of Patients Diagnosed with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome) in the United ...

As we navigate through 2025, the American healthcare system stands at a critical juncture. The demographic shifts that have been gradually unfolding are now accelerating, creating challenges that ...

Well before a human receives the first dose of an experimental drug, it’s evaluated in an animal to test for toxicity. Monkeys are often chosen for their genetic similarities to humans, and safe ...

Wegener's granulomatosis (newly renamed granulomatosis with polyangiitis [WG/GPA]) is a granulomatous autoimmune inflammatory disorder of unknown etiology that is associated with anti-neutrophil ...

Dr. Margot E. Manning (Medicine): A 32-year-old woman was admitted to this hospital because of flank pain, fever, and hypoxemia. Two weeks before the current presentation, sharp, intermittent pain ...

granulomatosis, or SLE. “We look forward to generating data from these clinical trials in autoimmune disease,” states Aslan. While an exciting clinical immunotherapy, CAR T-cell therapeutics ...

Retrograde cricopharyngeal dysfunction (R-CPD) is a little-known disorder first identified in 2019. It causes an inability to burp, accompanied by debilitating symptoms such as bloating, chest ...

eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome. The drug remains one of GSK's top products, with sales of £856 million ($1.1 billion) in the first half of this year ...